Amneal Pharmaceuticals (AMRX) 10-K2022 FY Annual report

Filed: 3 Mar 23, 5:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: aBLA, ABR, abstinence, accessible, adequacy, Aetna, altogether, Amphastar, analogized, bag, Barbara, batch, behavioral, Bexar, BLA, bladder, born, breakthrough, broadly, BsUFA, built, cap, catastrophic, cell, Century, cert, children, codified, convincing, Cook, copay, corruptly, creation, culminate, deadline, Dealer, deep, deepened, DEIB, destruction, digital, disaster, Eaton, element, email, endocrine, enterprise, escrow, esmolol, EUA, exam, expedite, expedited, explore, exploring, expropriation, faith, fast, fault, fifty, Filgrastim, FIN, Finnish, floor, Flynetra, fuel, futility, Gary, gastric, gastrointestinal, gave, GCP, GDPR, gene, genericize, globe, Golden, granule, hardware, Hatch, hoc, hosted, hybrid, hydrochloride, hygiene, infiltration, instruction, insulin, intentionally, interstate, investigatory, IRA, IRB, judgement, Kathryn, KRONOTEC, library, licensure, listening, logistic, loyalty, Martin, metabolism, MLP, molecule, MTP, muscle, NAS, neonatal, Neulasta, Neupogen, NIST, nonclinical, noncompliance, notably, notification, onset, onsite, Ontario, Orion, osmotic, overlap, pace, PDUFA, Pegfilgrastim, permissible, PHI, philanthropic, PII, pilot, plead, pled, poll, predominantly, priority, propriety, pulsatile, qualification, quota, rare, reciprocal, recommence, Releuko, reproductive, rescission, RLD, rolled, rollout, safeguard, satisfactory, sequential, shortened, slight, staffing, stakeholder, standalone, statewide, substance, Suffolk, sunset, swingline, syndrome, tachycardia, testimony, therapy, Thiele, threaten, tissue, titled, tolerance, tool, Toronto, Tort, TPG, tract, transgender, transparency, transparently, Truist, tsunami, twenty, unhedged, unjustly, unstable, upcoming, upper, vacating, vii, visiting, wait, waived, Watson, Waxman, willingly, wound, WV, Zealand

Removed: acknowledged, advantaged, AG, AI, allocating, answer, appellate, arbitrate, arbitration, array, asserted, CA, carryforward, chewable, comparatively, compel, core, Creo, Curacao, decommissioning, delivered, denial, Deutschland, discrepancy, dismantling, Disqualify, distributed, divestiture, Emverm, endocrinology, expectation, FCPA, Germany, GlaxoSmithKline, goal, Hayward, headcount, hookworm, inclusive, indemnifying, intention, Interpharm, Kingdom, labeler, Lannett, largely, likewise, Luxembourg, mark, mebendazole, mg, mixed, month, noticed, notified, ocular, opening, optimize, ordinarily, parasitic, pinworm, praecipe, precautionary, ready, reargument, reclassification, reissued, rendering, repricing, restraint, resubmitted, retired, roundworm, SAB, separation, Shortly, simplified, Sirona, skin, subtracting, successor, supportive, Tecum, TSR, unasserted, USA, vested, Wellbutrin, whipworm, XL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AMRX transcripts

AMRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Amneal Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2022 (the “Report”), Chirag Patel, President and Co-Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


March 3, 2023	By:	/s/ Chirag Patel
		Chirag Patel
		President and Co-Chief Executive Officer
		(Co-Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.